Two large-scale clinical studies have proved that SIM01 enhances immunity, reduces the risk of infection, and improves quality of life.
Since the emergence of the novel virus, public awareness of human immunity has greatly increased. Although the epidemic is gradually subsiding, many recovered patients are still troubled by various sequelae symptoms. Recently, two large-scale clinical studies conducted by the Faculty of Medicine of a Renowned University in Hong Kong have found that the G-NiiB Immunity formula SIM01 can improve the gut microbiota, enhance immunity to fight against bacterial and viral (including novel virus) invasion, and significantly improve various sequelae symptoms of the novel virus and enhance overall quality of life.
Large-Scale Double-Blind Clinical Study: IMPACT Study
In October 2022, the Faculty of Medicine of a Renowned University in Hong Kong announced the results of a large-scale double-blind clinical study called the IMPACT Study. The study recruited 453 individuals aged 65 or above. Participants received their first dose of a novel virus vaccine one week before or after the study and were randomly assigned to receive either a three-month course of the probiotic formula SIM01 or a placebo containing vitamin C (control group). This study employed a rigorous randomized, double-blind, placebo-controlled trial design and used precise metagenomic analysis to assess whether SIM01 could restore a healthy gut microbiota and enhance immunity to resist bacterial and viral infections.
The results showed that SIM01 enhanced immunity, reduced the risk of novel virus infection by 91%, reduced the risk of other viral and bacterial infections by 66%, and reduced the side effects of the novel coronavirus vaccine by 77%. Furthermore, compared to the control group, the SIM01 group experienced a 100% improvement in overall quality of life, including better sleep quality, more positive mood, and improved skin quality.
Large-Scale Triple-Blind Clinical Study (RECOVERY Study)
In May 2023, the Faculty of Medicine of a Renowned University in Hong Kong released the results of a large-scale triple-blind clinical study called RECOVERY Study. The study recruited 463 recovered novel virus patients, approximately 70% of whom were diagnosed with novel virus in 2022. Participants were randomly assigned to the SIM01 group and the control group. The former took the SIM01 formula for six months, while the latter took a placebo containing vitamin C for six months. This study aimed to evaluate whether the SIM01 formula could improve other post-novel virus sequelae symptoms. In addition to clinical assessment, the research team also used metagenomics to compare participants' stool samples to analyze changes in their gut microbiota.
The results showed that taking the SIM01 formula for six months effectively alleviated post-novel virus sequelae. Compared with placebo, the relative improvement rate of sequelae symptoms of the five types of novel coronaviruses increased, including overall discomfort (+30.8%), gastrointestinal problems (+29.8%), fatigue (+47.4%), difficulty concentrating (+61.8%), and memory problems (+56.1%), and it also showed greater efficacy in regulating the gut microbiota.
The research team will continue to dedicate itself to developing more clinical applications of gut microbiota to help the public rebuild a healthy gut microbiota and improve their quality of life.
Purchase link:
https://g-niib.com/products/g-niib-immunity-plus-sim01
https://g-niib.com/products/g-niib-immunity-elite-sim01
